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Background: Despite the precise pathogenesis of atopic dermatitis (AD) is unknown, an immune dysregulation
that causes Th2-predominant inflammation and an intrinsic defect in skin barrier function are currently the two
major hypotheses, according to the so-called outside-inside-outside model. Mast cells (MCs) are involved in AD both
by releasing Th2 polarizing cytokines and generating pruritus symptoms through release of histamine and tryptase.
A link between MCs and skin barrier defects was recently uncovered, with histamine being found to profoundly
contribute to the skin barrier defects.
Palmitoylethanolamide and related lipid mediators are endogenous bioactive compounds, considered to play a
protective homeostatic role in many tissues: evidence collected so far shows that the anti-inflammatory effect of
palmitoylethanolamide depends on the down-modulation of MC degranulation.
Based on this background, the purpose of the present study was twofold: (a) to determine if the endogenous levels
of palmitoylethanolamide and other bioactive lipid mediators are changed in the skin of AD dogs compared to
healthy animals; (b) to examine if MC number is increased in the skin of AD dogs and, if so, whether it depends on
MC in-situ proliferation.
Results: The amount of lipid extract expressed as percent of biopsy tissue weight was significantly reduced in AD
skin while the levels of all analyzed bioactive lipid mediators were significantly elevated, with palmitoylethanolamide
showing the highest increase.
In dogs with AD, the number of MCs was significantly increased in both the subepidermal and the perifollicular
compartments and their granule content was significantly decreased in the latter. Also, in situ proliferation of MCs was
documented.
Conclusions: The levels of palmitoylethanolamide and other bioactive lipid mediators were shown to increase in AD
skin compared to healthy samples, leading to the hypothesis that they may be part of the body’s innate mechanisms
to maintain cellular homeostasis when faced with AD-related inflammation. In particular, the increase may be considered
a temptative response to down-regulating the observed elevation in the number, functionality and proliferative state of
MCs in the skin of AD dogs. Further studies are warranted to confirm the hypothesis.
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Atopic dermatitis (AD) is an itchy chronic skin disease
frequently observed in dogs. Although not completely
understood, the aetiology of the disease is multifactorial
and depends on complex interactions between genetic
and environmental factors. An immune dysregulation that
causes Th2-predominant inflammation and an intrinsic
defect in skin barrier function are currently the two major
hypotheses, both for human and canine AD [1-3]. Strong
debate is still ongoing on whether changes observed in
skin barrier function are the cause or consequence of AD
inflammatory changes [4].
It is generally assumed that skin mast cells (MCs) con-
tribute to AD inflammation [1,5], as recently supported by
two outstanding scientific papers [6,7]. MCs are immune-
inflammatory tissue-localized cells and although they res-
ide in almost all of the major organs and tissues of the
body, they are strategically located at host/environment in-
terfaces, such as the skin, the gastrointestinal and urogeni-
tal tracts, and the airways. Yet, they are present also in
many other tissues, like the heart, brain, kidneys and joints
[8,9]. Once activated by either IgE-dependent or IgE-
independent, MCs degranulate, a process that results in
the exocytosis of an impressive array of pro-inflammatory
and immuno-regulatory mediators that initiate immediate
phase inflammatory responses and late phase reactions
[10,11]. Particularly, MCs release Th2 polarizing cytokines
such as IL4, IL10, and IL13 which can induce a stimulated
naive CD4+ T cell to become a Th2 cell when activated
in the lymph node [12]. Moreover, they contribute to
AD development by the generation of pruritus symp-
toms through release of histamine and tryptase [13-17].
MCs are bone marrow-derived cells that mature to be-
come tissue-resident MCs after localizing in appropriate
tissues. Stem cell factor (SCF), a fibroblast/keratinocyte
derived chemokine (also known as c-kit or CD117 lig-
and) has been shown to be necessary for the maturation
and proliferation of tissue-resident MCs, and to increase
in both lesional and nonlesional skin of humans and
dogs with AD [18]. Proliferation of skin MCs has been
documented in human patients with AD [19], and MCs
dispersed from adult human skin have been shown to
proliferate under appropriate conditions [20]. Albeit an
increase in MC number has been occasionally documented
in canine AD [21,22], a study performed in healthy and
AD dogs failed to confirm MC proliferation in the skin
[23]. Moreover, another study reported MC density to be
significantly lower in the lesional and nonlesional skin of
AD dogs than in the skin of control animals [24].
Skin barrier dysfunction in canine AD has recently been
explored. It mainly consist of abnormal stratum corneum
ultrastructure and decreased ceramides, i.e., a family of
lipid molecules, composed of sphingosine and a fatty acid
[25-29]. Surprisingly, a link between MCs and skin barrierdefects was recently uncovered, with histamine – the best
known MC mediator - being found to decrease the ex-
pression of tight junction proteins, leading to the forma-
tion of a defective skin barrier [30].
N-acylethanolamines (NAEs) and 2-arachidonoyl-glycerol
(2-AG) are bioactive derivatives of fatty acids, which have
been identified in almost all mammalian tissues and body
fluids [31-33]. Upon the identification of a particular
NAE, i.e., N-arachidonoyl-ethanolamine (anandamide,
AEA) as the endogenous ligand for the cannabinoid re-
ceptors (CBs) in the early nineties, interest in these
bioactive lipid compounds dramatically increased [34].
N-palmitoyl-ethanolamine (PEA), a shorter and fully satu-
rated AEA analogue, was also paid much attention in view
of its general anti-inflammatory, pain relieving and neuro-
protective properties [32,35,36]. Endogenous PEA as well
as other NAEs are considered to play a protective homeo-
static role in many tissues, including the skin [32,37].
Evidence collected so far shows that the broad biophar-
macological effects of PEA mainly depend on the down-
modulation of MC degranulation [38-40].
Based on this background, the purpose of the present
study was twofold: (a) to determine if the endogenous
levels of PEA and other bioactive lipid mediators are chan-
ged in the skin of AD dogs compared to healthy animals;
(b) to examine if MC number is increased in the skin of
AD dogs and, if so, whether it depends on MC in-situ
proliferation.
Methods
Animals
In a prospective study, 5 healthy dogs (1 male and 4
females; age range, 4 to 13 years) and 5 dogs with AD
(2 males and 3 females; age range, 1 to 11 years) were
included in the study. Healthy dogs were client-owned
dogs admitted for neutering. Dogs with AD were client-
owned dogs referred for dermatologic problems; six or
more of the criteria provided by Favrot et al. [41] were ful-
filled for each of these subjects. Dogs with AD had clinical
signs of erythema, alopecia, pruritus, and mild crusting of
skin and had positive results for intradermal allergen test-
ing for both outdoor and indoor environmental allergens,
which supported the clinical diagnosis of AD. Other prur-
itic diseases, such as flea allergy dermatitis, adverse food
reactions, sarcoptic mange, Malassezia dermatitis and su-
perficial bacterial infections were excluded. In particular,
all AD dogs underwent flea control measures and were fed
a hypoallergenic restriction diet for 8 weeks prior to col-
lection of skin samples to exclude allergies to fleas or food
as possible causes of AD. When needed, dogs were treated
for secondary yeast or bacterial infections of skin. Immedi-
ately before collection of skin samples, cytological examin-
ation of skin at planned collection sites was performed for
each dog with AD; bacteria and fungi were not detected.
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discontinued at least 2 to 3 weeks prior to collection of
skin samples in these dogs. To avoid bias attributable to in-
clusion of skin samples with AD lesions from various ana-
tomic sites, only samples of skin lesions from the ventral
aspect of cervical region and axillae of dogs were obtained.
Samples collected from the abovementioned dogs served
for total lipid and NAEs and 2-AG quantification, morpho-
metrical and densitometrical assessment of MCs. Evaluation
of MCs proliferation index (Pi) was performed in dogs with
AD only.
Institutional ethical committee approval was not required
for the study because AD skin samples were obtained and
histologically examined for diagnostic purposes. Written in-
formed consent was obtained from owners of all dogs for
inclusion of their dogs in the study.
Ten dogs with previously diagnosed AD were included
in the study for MC Pi assessment only, to obtain statisti-
cally reliable data: paraffin embedded skin samples were
selected from the dermatohistopatholology archive of our
institution. The diagnosis of AD was retrospectively re-
evaluated and based on the presence of six or more of the
set of criteria proposed by Favrot [41]. It was known that
the dogs, when needed, had been treated for yeasts and/or
bacterial secondary infections and that neither bacteria
nor fungi were histological detected.
Collection of tissue samples
Skin samples were obtained from the abdominal region
of each of the 5 healthy dogs during deep anesthesia
(isoflurane) for surgery (i.e., neutering) and from each of
the 5 client-owned dogs with AD. These latter dogs were
sedated with butorphanol tartrate and medetomidine
hydrochloride for intradermal allergen testing; skin sam-
ples were collected by use of local anesthesia with lido-
caine (2%).
Two 6-mm punch biopsies were collected from adjacent
sites: neutering area in healthy dogs and lesional areas in
AD subjects. One biopsy was snap-frozen in liquid nitrogen
then stored at −80° until performing lipid extraction. The
second biopsy was promptly immersed in a 10% neutral-
buffered formalin solution (pH 7,4) and routinely processed
for paraffin embedding. Five μm thick sections were stained
with haematoxylin and eosin (H&E) and toluidin blue (TB)
and examined via light microscopy. H&E stained sections
were used for the general assessment of histological lesions
while TB sections served for morphometrical and densito-
metical evaluation.
Lipid extraction and quantification
Skin biopsies were homogenized in chloroform/methanol/
Tris–HCl 50 mM pH 7.4 (2 : 1 : 1, v/v) containing 10
pmol of [2H]8-AEA, [2H]4-PEA and [2H]4-OEA, and
50 pmol of [2H]5-2-AG as internal deuterated standards(purchased from Cayman Chemicals, Ann Arbor, MI). The
lipid-containing organic phase was dried down, weighed
and prepurified by open-bed chromatography on silica gel.
Fractions obtained by eluting the column with 9 : 1 (by
vol) chloroform/methanol were analysed by liquid chroma-
tography– atmospheric pressure chemical ionization–mass
spectrometry (LC– APCI–MS) by using a Shimadzu HPLC
apparatus (LC-10ADVP) coupled to a Shimadzu (LCMS-
2010) quadrupole MS via a Shimadzu APCI interface. LC–
APCI–MS analyses were carried out in the selected ion
monitoring mode, using m/z values of 356 and 348 (mo-
lecular ions +1 for deuterated and undeuterated AEA), 304
and 300 (molecular ions +1 for deuterated and undeuter-
ated PEA), 330 and 326 (molecular ions +1 for deuterated
and undeuterated OEA), and 384.35 and 379.35 (molecular
ions +1 for deuterated and undeuterated 2-AG). AEA,
OEA, PEA and 2-AG concentrations were calculated by
isotope dilution and are expressed as pmol per g of wet tis-
sue weight. The concentrations of 2-AG were obtained by
adding up to the amounts of the 2-isomer also those of the
1(3)-isomer, which mostly originates from the isomeriza-
tion of the former during work-up.
Morphometry and densitometry
The distribution of MCs and their granule content were
assessed at high power field (magnification ×400) from
the superficial (subepidermal) and perifollicular dermis.
Toluidine blue cells were counted in 10 selected high
power fields (HPFs) per section (400×). Values were ex-
pressed as number of counted cells per mm2. On the same
selected HPFs cytoplasmic densitometry was assessed by
applying the same pre-defined macro. Briefly, a binary
image (gray levels) was obtained and granule content was
measured as a mean gray value, as previously reported
[38] (Figure 1). The Lucia (Nikon, Japan) analyser system
was used.
Immunohistochemistry
Superfrost-Plus mounted slides were used to detect prolif-
erating MCs by double immunostaining with anti -cd117
and -Ki67 antibodies. Cd117 identifies the stem cell factor
ligand receptor which is expressed on the cell membranes
of both mature MCs and their earliest precursors. Ki67 is
a cellular marker for proliferation present during all active
phases of the cell cycle but absent from resting cells, the
number of Ki67 labeled cells (nuclear immunoreactivity)
on 100 cells (%) is worldwide accepted as the proliferation
index (Pi). The immunohistochemical procedure was per-
formed as follows. After deparaffinization and rehydrating,
quenching of endogenous peroxidases was carried out by
incubation with 3% H2O2 in distilled water (30 min, RT).
Antigen unmasking was performed in citrate buffer pH 6
(UCS Diagnostic S.r.l., Morlupo, Rome, Italy) in micro-
wave for 15 minutes. Non-specific binding was prevented
Figure 1 Densitometry procedure. a) Initial Toluidine blue stained
captured image; b) binary (gray scale) image; c) red areas indicate
measured granules.
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(Super Block, Scy Tek Laboratories, Logan, UT, USA)
(10 minutes, RT). Slides were subsequently incubated with
the mouse monoclonal anti-Ki67 primary antibody (cat.
M3060, Spring Bioscience, Pleasanton, CA, USA) 1:100 inPBS-Tween (PBT-1099 - UCS Diagnostic S.r.l., Morlupo,
Rome, Italy) overnight at 4°C. The ULTRATEK-HRP kit
(HS8-DAB Ultra Tek HRP, Scy Tek Laboratories, Logan,
UT, USA) was used to visualise the immunoreaction. Glass
slides were therefore rinsed in PBST for 10 minutes and
incubated with a serum-free protein block (Super Block,
Scy Tek Laboratories, Logan, Utah, U.S.A.) for 10 mi-
nutes. The rabbit polyclonal anti-CD117 antibody (cat.
E1440, Spring Bioscience, Pleasanton, CA, USA) 1:400
in PBST (UCS Diagnostic S.r.l., Morlupo, Rome, Italy)
was used (1 hour, RT) and the same ULTRATEK-HRP
kit was used for secondary antibody and streptavidin-
peroxidase complex. Immunoreactivity was visualised
by a different chromogen (Vector® VIP, Vector Laboratories,
Burlingame, CA, USA). Sections were then counterstained
with Haematoxylin, dehydrated and mounted with a per-
manent mounting medium.
Statistical analysis
The amounts of lipid extracts, NAEs and 2-AG were com-
pared by the Wilcoxon signed-rank test. MCs counts and
densitometry values were compared by the unequal vari-
ance t-test. For Pi mean percentage number of Ki67 immu-
nolabelled MCs and standard deviation were calculated.
Results
Total lipid, NAE and 2-AG quantification
The amount of lipid extract expressed as percent of bi-
opsy tissue weight was significantly reduced (~6-fold) in
the lesional skin of AD dogs, as compared to control dogs
(35.63% vs 5.79% p < 0.05). Conversely, the levels of all
analysed NAEs and 2-AG were significantly elevated (p <
0.05). In particular PEA levels showed the highest increase,
being more than 30-fold higher in AD lesional skin than in
normal non-atopic skin. OEA and 2-AG showed a 30- and
14-fold increase in AD lesional skin than in normal skin,
respectively while AEA showed only a ~6-fold increase
(Figure 2).
Histological evaluation
Changes were not observed in skin of healthy dogs.
Histopathological findings of specimens obtained from
dogs with AD supported the clinical diagnosis. Briefly, a
moderated epidermal hyperplasia with mild spongiosis
was observed in all cases. Superficial dermal changes were
related to a perivascular to interstitial infiltrate mainly
composed by MCs, lymphocytes and few histiocytes and
neutrophils. The superficial vascular plexus was promin-
ent with reactive endothelial cells. Minimal subepidermal
and perivascular oedema was observed (Figure 3).
Mast cell morphometry and densitometry
Toluidine blue positive (metachromatic) MCs in nor-
mal skin were 53.90 ± 16.64 cells/mm2 and 34.34 ± 5.06
Figure 2 Bar graphs showing lipid extract quantification. a)
lipid extract expressed as percent of biopsy tissue weight in control
animals and dogs with atopic dermatitis; b) Quantification of
different NAEs and 2-AG in control animals and dogs with atopic
dermatitis. Asterisks indicate statistically significant differences (p < 0.05);
AD = Atopic dermatitis.
Figure 3 Skin histopathology of dogs with AD. a) Regular
epidermal hyperplasia with mild spongiosis and superficial
perivascular infitrate composed of lymphocytes, MCs and a few
neutrophils; H&E stained section; b) Toluidine blue stained section
showing methacromatic MCs infiltrating the superficial dermis.
Scale bars = 100 μm.
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cular areas, respectively. In the same selected areas, dogs
with AD showed higher values (131.75 ± 45.69 cells/mm2
and 101.58 ± 21.84 cells/mm2). The difference was statisti-
cally significant for both sites (p < 0.01). In the perifollicu-
lar areas, a statistically significant decrease in MC granule
content was observed in AD compared with normal ca-
nine skin (p < 0.01). Such a difference was not observed in
the subepidermal compartment (Figure 4).Proliferation index of mast cells
When the double immunostaining approach was per-
formed, membrane CD117 immunoreactivity confirmed
the presence of several MCs; some of them were also
positive to the nuclear antigen Ki67, thus demonstrating
their proliferating activity (Figure 5). Scattered individual
or grouped keratinocytes in the basal layer of epidermis
were also reactive to Ki67 and their proliferating status
served as an internal positive control for the Ki67 reac-
tion. Data analysis of the 5 dogs with AD prospectively
selected showed a Pi mean value of 5.68 ± 2.25 while in
the retrospectively included 10 dogs the mean value was
11.11 ± 6.47. When a cumulative analysis was performed,the obtained Pi value was 9.30 ± 5.95. MCs proliferation
index values are reported in Table 1.Discussion
The statistically significant decrease in total lipid content
in the skin of dogs with AD showed in the present study
fits with the documented skin barrier impairment in ca-
nine hypersensitivity skin disorders [3]. To the best of
our knowledge, this is the first report showing the de-
crease in total skin lipid content in canine AD, previous
studies having focused on particular composition defects
(i.e., ceramides, free fatty acid, lamellar bodies) [42]. Par-
ticularly, abnormal stratum corneum ultrastructure and
disorganized lipid lamellae were found in nonlesional and
lesional skin of spontaneous and experimentally-induced
canine AD [27,43-45]. Moreover, lower proportion of cera-
mides were found in both nonlesional and lesional skin of
dogs with AD compared to that of normal dogs [20,24,39].
Figure 4 Bar graphs showing MC count (left) and MC granule content (right) in control animals and dogs with atopic dermatitis.
Asterisks indicate statistically significant differences (p < 0.01).
Table 1 MC proliferation index (Pi) data
Group Case No. No. Areas CD117 + CD117 + / Ki67 + Pi (%)
1 1 16 56 4 7,14
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levels of PEA and related lipid mediators (i.e., OEA and
2-AG) were shown here to increase in AD samples com-
pared to healthy ones. Among all the analysed bioactive
lipid compounds, PEA levels were more than 30-fold higher
in AD lesional skin compared to normal non-atopic skin.
Moreover, if one considers the total decrease of lipid con-
tent, the overall increase of PEA and the other examined
lipid mediators is dramatic and once more might witness
the role of NAEs and 2-AG in cellular homeostasis in the
face of external stressors provoking, for example, inflamma-
tion. Currently, it is widely accepted that the endogenous
formation of these bioactive lipid mediators plays a pro-
homeostatic role, by being part of a protective response to
cellular injury [32,46]. In particular, PEA levels have been
measured in mammalian skin [47-50] and found to change
in response to stressful conditions, both in animal models
[51] and epidermal cell cultures [52]. The increase in tissueFigure 5 Double immunohistochemistry with CD117 and Ki67.
Mast cells are CD117 positive membrane stained cells; One of them
(arrowhead) shows also nuclear immunoreactivity (Ki67) indicating
its proliferating status. Streptavidin-peroxidase method.
Scale bar = 20 μm.levels of PEA is now considered an auto-protective mech-
anism, while the decrease is usually regarded as an exhaus-
tion of the response [53].
The hypothesis is highly substantiated by the favourable
effects of PEA administration: mice with contact dermatitis
[50], hypersensitive Beagle dogs [54] and cats with eosino-
philic granuloma [38] all benefited from PEA treatment in
terms of reduced allergic skin reactions.
Although the exact mechanism of PEA action is still a
matter of debate, it is generally assumed that it depends
on a multitarget pathway signalling, with the direct or
indirect engagement of different receptors, such as CB,
PPAR, TRPV1 and GPR55 receptor [32,34,37,53]. In line
with this, we recently reported the immunolocalization2 17 54 3 5,56
3 18 80 6 7,50
4 14 53 1 1,89
5 23 158 10 6,33
Group 1 mean 5,68
2 1 25 112 7 6,25
2 15 46 6 13,04
3 25 108 11 10,19
4 11 37 4 10,81
5 20 61 3 4,92
6 20 51 12 23,53
7 13 44 8 18,18
8 20 104 15 14,42
9 22 89 7 7,87
11 25 106 2 1,89
Group 2 mean 11,11
Cumulative mean 9,30
Group 1 = prosective study. Group 2 = retrospective study.
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latter showing increased expression of these receptors [55].
Moreover, CB1 stimulation has been recently reported to
limit excessive activation of hair follicle-associated MCs
[56]. Compounds like PEA and OEA, which do not dir-
ectly activate CB receptors, might instead produce anti-
inflammatory actions via other targets such as PPARα and
TRPV1 [57,58]. On a cellular level, the main target of PEA
is considered to be the MC [32-34].
We found MC density to increase both in the subepi-
dermal and the perifollicular compartment of atopic ani-
mals compared to healthy controls. Although it could be
speculated that different sample locations (i.e., ventral
neck in AD dogs versus abdominal region in healthy dogs)
could partially explain the difference, one should consider
that the distribution of MCs at various skin sites of dogs
does not seem to differ among body regions, except for
ears (pinnae) where MC number is significantly higher
[59-61]. Moreover, our results are consistent with the pre-
viously shown increase in MC density in various skin sites
of AD dogs compared to controls [22,62]. Nevertheless the
overall scenario on the topic is still somewhat conflicting,
MC numbers having been reported not to differ between
healthy and AD canine skin [24]. A recent review [56]
summarizes the main findings on MC number in human
AD [63]: in acute lesions, MCs are normal in number but
show degranulation [64]. In chronic lesions, however, their
numbers are significantly increased, especially in areas of
lymphocytic infiltration in the papillary dermis [64,65].
Our densitometric data suggest a different functionality
of the two anatomic MC populations examined, since de-
granulation was found to be more prominent in perifolli-
cular than subepidermal MCs. A specific MC population
has been recently characterized in humans, harbouring
the perifollicular connective tissue sheath, thus accounting
for a possible different role of the two differently distrib-
uted MC populations [56]. A selective degranulating state
of atopic skin MCs was reported in dogs by Welle and col-
leagues [24] who found a significantly lower MC density
in both lesional and nonlesional skin samples of atopic
dogs than in the skin of control dogs when stained for the
two MC-specific proteases, i.e., tryptase and chymase.
Moreover, our findings are consistent with those recently
found by an electron microscopic study, showing that
MCs from canine skin with AD exhibited piecemeal, ana-
phylactic and mixed pattern degranulation [22].
Given our morphometric data on the significantly in-
creased MC count both in the subepidermal and perifolli-
cular areas (i.e., almost a 3-fold higher value than in control
skin), we asked if this could partly rely on in situ prolifera-
tion. We actually found Ki67-CD117 double positive cells,
i.e. skin cells expressing the transmembrane tyrosine kinase
growth factor receptor (c-kit or CD117 or SCF receptor) to-
gether with the proliferation nuclear marker Ki67. Theseare proliferating MCs, since CD117 immunoreactivity in
canine skin clearly identify MCs [66]. These results support
the hypothesis that during AD, accumulation of dermal
MCs does not arise exclusively from recruitment of bone-
marrow-derived precursor cells, as previously stated [23],
but also partially from in situ proliferation. Although one
cannot rule out the hypothesis that Ki67-labelled cells im-
mature MCs which have just left the bloodstream to infil-
trate the dermis and may be related to enhanced migration
of MC precursors from the bloodstream as suggested by
previous studies [23], the identification of in situ prolifera-
tion of resident MCs in the connective outer root sheath of
follicles by Sugavara et al. [56] strongly support our hypoth-
esis of in situ proliferation of resident MCs in canine AD.
Conclusions
The current study adds new information on the so-called
outside-inside-outside pathophysiological model of canine
AD. At the skin barrier side (i.e., outside), our findings
show a decreased of total lipid content. At the immune-
inflammatory side of the disease (i.e. inside) we have shed
new light on the body own “inflammatory dualism”, with
an increased MC density and activation state and a con-
currently increased production of the endogenous anti-
inflammatory armamentarium (i.e., increased bioactive lipid
compounds and especially PEA in the lesional skin of AD
dogs compared to controls). Further studies are needed to
deeply explore the eventual interplay among the changes
reported here and to investigate whether PEA and related
endocannabinoids play indeed an adaptive protective role
in canine AD.
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